Literature DB >> 2737228

Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children.

J A Martyn1, D J Greenblatt, J Hagen, D C Hoaglin.   

Abstract

We have studied the mechanisms of the increased dosage requirements of the H2-receptor antagonist cimetidine in paediatric burned patients in a pharmacokinetic and pharmacodynamic study. Cimetidine (10-15 mg.kg-1) was given to 21 burned children and multiple blood samples were obtained for determination of plasma cimetidine concentrations and pharmacokinetic analysis. The relation of gastric pH to plasma cimetidine concentrations was studied in five of these children who had nasogastric tubes. In an additional four patients the effects of cimetidine on gastric pH were studied during a continuous infusion of cimetidine, which maintained steady-state plasma cimetidine concentrations above 0.5 microgram.ml-1. The mean (SEM) clearance of cimetidine in burned children was 16.22 ml.kg-1 and cimetidine half-life was 1.06 h. The cimetidine clearance and half-life values were significantly higher in burned children compared with our previously reported values for normal adult patients, 8.2 ml.min.kg-1 and 2.21 h respectively. Endogenous creatinine clearance normalized to 70 kg in burned children was 190 ml.min-1. In burned children 41% of the dose of intact cimetidine was excreted during 8 h of the study compared with 45% excretion during 24 h in healthy adult controls previously reported. The correlation coefficient between creatinine and cimetidine clearances was 0.93 (r2 = 0.85). The plasma concentration of cimetidine needed to increase gastric pH to greater than or equal to 4.0 was greater than or equal to 1.0 micron.ml-1, which contrasts with the value of greater than 0.5 micron.ml-1 required for adult burned patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737228     DOI: 10.1007/bf00558296

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  Transient neutropenia in a patient receiving cimetidine.

Authors:  M H Ufberg; C M Brooks; P R Bosanac; J E Kintzel
Journal:  Gastroenterology       Date:  1977-09       Impact factor: 22.682

2.  Acute gastroduodenal disease after thermal injury. An endoscopic evaluation of incidence and natural history.

Authors:  A J Czaja; J C McAlhany; B A Pruitt
Journal:  N Engl J Med       Date:  1974-10-31       Impact factor: 91.245

3.  Curling's ulcer: a clinical-pathology study of 323 cases.

Authors:  B A Pruitt; F D Foley; J A Moncrief
Journal:  Ann Surg       Date:  1970-10       Impact factor: 12.969

Review 4.  Clinical pharmacology and drug therapy in the burned patient.

Authors:  J Martyn
Journal:  Anesthesiology       Date:  1986-07       Impact factor: 7.892

5.  Failure of gastric pH control by antacids or cimetidine in the critically ill: a valid sign of sepsis.

Authors:  L F Martin; M H Max; H C Polk
Journal:  Surgery       Date:  1980-07       Impact factor: 3.982

Review 6.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Duodenal and gastric ulceration after burning.

Authors:  S Sevitt
Journal:  Br J Surg       Date:  1967-01       Impact factor: 6.939

8.  Cimetidine affords protection equal to antacids in prevention of stress ulceration following thermal injury.

Authors:  H P McElwee; K R Sirinek; B A Levine
Journal:  Surgery       Date:  1979-10       Impact factor: 3.982

9.  Cimetidine pharmacokinetics and dosage requirements in children.

Authors:  A Somogyi; M Becker; R Gugler
Journal:  Eur J Pediatr       Date:  1985-05       Impact factor: 3.183

10.  Cimetidine plasma concentration-response relationships.

Authors:  R Gugler; G Fuchs; M Dieckmann; A A Somogyi
Journal:  Clin Pharmacol Ther       Date:  1981-06       Impact factor: 6.875

View more
  5 in total

Review 1.  Pathophysiology and pharmacokinetics following burn injury.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery.

Authors:  G Kraus; D R Krishna; D Chmelarsch; M Schmid; U Klotz
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 3.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics in patients with burns.

Authors:  U Jaehde; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.